

Virus Manufacturing

ABL has a long history of development and manufacturing of preclinical and clinical virus-based biologics. From 30 years of groundbreaking work with HIV to supporting the latest gene therapy technologies, ABL offers a comprehensive portfolio of services for the effective design, development, manufacturing and analytical testing of vaccine and virus vector products.

Interested in knowing more about our virus manufacturing services?

[Contact Us](#)



As a leading CMO in virus manufacturing,

ABL offers:

- Upstream and Downstream Process Development
- Master and Working Cell Banks
- Master and Working Viral Banks
- Adherent production in Roller Bottle, Cell Stacks / Factories, and HYPERstacks
- Suspension production in Single-use Bioreactors ranging from 2L – 400L working volume.
- Bulk Drug Substance (BDS) Scale-up and Engineering (non-GMP) runs
- Bulk Drug Substance (BDS) GMP runs
- Drug Product (DP) Filling
- Analytical Development and Assay Qualification
- In-process and Release QC testing
- Stability Studies
- CMC support
- Comprehensive Program Management

ABL's expertise in virus manufacturing includes:

- Adenovirus
- Adeno-associated virus (AAV)
- Influenza
- Poxviruses, i.e. Modified Vaccinia Ankara (MVA), Vaccinia
- Retroviruses, i.e. HIV, Lentivirus

- Rhabdovirus, i.e. Maraba virus (oncolytic virus), Vesicular stomatitis virus (VSV)
- Virus-like particles (VLPs)
- Lytic and non-lytic viruses
- Enveloped and non-enveloped viruses